

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository:<https://orca.cardiff.ac.uk/id/eprint/131015/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Gadsbøll, Kasper, Petersen, Olav Bjørn, Gatinois, Vincent, Strange, Heather , Jacobsson, Bo, Wapner, Ronald, Robert Vermeesch, Joris, Vogel, Ida, Shand, Antonia, Nowakowska, Beata, Peterlin, Borut, Machtejeviene, Egle, Sethna, Farah, Stipoljev, Feodora, Szirko, Ferenc, Romana Grati, Francesca, Minarik, Gabriel, Duncombe, Greg, Helmer, Hanns, Hardardottir, Hildur, Lebedev, Igor, Dickinson, Jan, Melo, Joana B., Edwards, Lindsay, Hui, Lisa, Srebniak, Malgorzata I., de Alba, Marta Rodriguez, Vedmedovska, Natalija, Calda, Pavel, Celec, Petet, Muller, Peter, Patsalis, Philippos, Popp, Radu, Liehr, Thomas, Moe Eggebø, Torbjørn, Stefanovic, Vedran and Velissariou, Voula 2020. Current use of noninvasive prenatal testing in Europe, Australia and the USA: A graphical presentation. *Acta Obstetricia et Gynecologica Scandinavica* 99 (6) , pp. 722-730. 10.1111/aogs.13841

Publishers page: <http://dx.doi.org/10.1111/aogs.13841>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See <http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



# Current use of Noninvasive Prenatal Testing in Europe, Australia and the USA: A graphical presentation

Kasper Gadsbøll, MD, Ph.d.-student<sup>1</sup>, Olav Bjørn Petersen, Professor<sup>1,2</sup>, Vincent Gatinois, PharmD, PhD<sup>3</sup>, Heather Strange<sup>4</sup>, Bo Jacobsson, Professor<sup>5</sup>, Ronald Wapner, Professor<sup>6</sup>, Joris Robert Vermeesch, Professor<sup>7</sup>, The NIPT-map study group\*, Ida Vogel, Professor<sup>8,9</sup>

## Affiliation

<sup>1</sup> Center for Fetal medicine, pregnancy and ultrasound, Copenhagen University Hospital, Rigshospitalet, Denmark

<sup>2</sup> Department of Clinical Medicine, University of Copenhagen, Denmark

<sup>3</sup> Chromosome genetics laboratory, CHU Montpellier, Univ. Montpellier, Montpellier, France

<sup>4</sup> Cardiff University (Centre for Trials Research), Wales, UK

<sup>5</sup> Sahlgrenska University Hospital, Gothenburg, Sweden

<sup>6</sup> Department of Obstetrics and Gynecology, Columbia University, New York, New York

<sup>7</sup> Department of Human Genetics, KU Leuven, Leuven, Belgium

<sup>8</sup> Department of Clinical Genetics, Aarhus University/Aarhus University Hospital, Denmark

<sup>9</sup> Center for Fetal Diagnostics, Aarhus University/Aarhus University Hospital, Denmark

## Corresponding author:

Kasper Gadsbøll

Center for Fetal medicine, pregnancy and ultrasound, Copenhagen University Hospital,  
Rigshospitalet, Blegdamsvej 9, 2200 Copenhagen N, Denmark

E-mail: [Kaspergadsboell@gmail.com](mailto:Kaspergadsboell@gmail.com)

Tel.: +45 61285267

## Word count:

~~2606~~2803/3000

## The NIPT-map study group\*

**Andrew McLennan**, University of Sydney, Australia;

**Beata Nowakowska**, Institute of Mother and Child, Warsaw, Poland;

**Borut Peterlin**, Clinical Institute of Clinical Genetics, Slovenia;

**Egle Machtejeviene**, Lithuanian University of Health Sciences, Lithuania;

**Farah Sethna**, Centenary Hospital for Women and Children, Canberra, ACT, Australia;

**Feodora Stipoljev**, Dept. Of Laboratory Cytogenetics, Clinic of Obstet. and Gynecol, Clinical Hospital "Sveti Duh", Zagreb, Faculty of Medicine, University of Osijek, Osijek, Croatia;

**Ferenc Szirko**, East-Tallinn Central Hospital, Estonia;

**Francesca Romana Grati**, TOMA Advanced Biomedical Assays S.p.A., Impact Lab Group, Italy;

**Gabriel Minarik, TrisomyTest Ltd., Bratislava, Slovakia**

**Glenn Gardner**, Maternal Health, Brisbane, Australia;

**Hanns Helmer, Medical University of Vienna, Austria**

**Hildur Hardardottir**, Landspítali, University Hospital and Livio, Reykjavik, Iceland;

**Igor Lebedev**, Research Institute of Medical Genetics, Tomsk National Research Medical Center of the Russian Academy of Science, Tomsk, Russia;

**Joana B. Melo**, Lab of Cytogenetics and Genomics, Faculty of Medicine, University of Coimbra, Portugal;

**Lindsay Edwards**, Royal Hobart Hospital, Tasmania, Australia;

**Lisa Hui**, University of Melbourne, Murdoch Children's Research Institute, Victoria, Australia;

**Malgorzata I. Srebniak**, Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, the Netherlands;

**Marta Rodriguez de Alba**, Genetics Department. Fundación Jiménez Díaz, Spain;

**Natalija Vedmedovska**, RSU-Rīga Stradins University; Rīga Maternity Hospital, Latvia;

**Pavel Calda**, Fetal Medicine Center, Department of Obstetrics and Gynaecology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic;

**Petet Celec, Institute of Molecular Biomedicine, Comenius University, Bratislava, Slovakia**

**Peter Muller**, Women's and Children's Hospital, Adelaide, Australia;

**Philippos Patsalis**, Founder & CEO, NIPD Genetics, Professor of Human Genetics, University of Nicosia Medical School, Cyprus;

**Radu Popp**, Genetics - Department of Molecular Sciences, Iuliu Hațieganu University of Medicine and Pharmacy Cluj-Napoca, Romania;

**Thomas Liehr**, University clinic Jena, Institute of Human Genetics, Germany;

**Torbjørn Moe Eggebø**, Center for fetal medicine, Trondheim University Hospital, Trondheim, Norway;

**Vedran Stefanovic**; Department of Obstetrics and Gynecology, Fetomaternal Medical Center, Helsinki University Hospital, Finland;

**Voula Velissariou**, BIOIATRIKI HEALTHGROUP, GREECE/NIPD Genetics, CYPRUS;

## Conflict of Interest statement

Ronald Wapner receives research support from Illumina, and Natera. The funding went directly to the department. All other authors declared no conflict of interest.

## Funding information

Ida Vogel is funded by a grant from the Novo Nordic Foundation: NNF16OC0018772

[Olav Bennike Bjørn Petersen holds a professorship funded by Novo Nordisk Foundation grant NNFSA170030576](#)

## Abstract (333 words/350 words allowed)

### Introduction

Noninvasive prenatal testing (NIPT), using cell-free fetal DNA, has increasingly been adopted as a screening tool for fetal aneuploidies. Several studies have discussed benefits and limitations of NIPT compared to both ultrasound and invasive procedures, but in spite of some shortcomings NIPT has become extensively used within the last five years. This study aims to describe the current use of NIPT in Europe, Australia and the USA.

### Materials and methods

We conducted a survey to describe the current use of NIPT. Colleagues filled in a simple email-based questionnaire on NIPT in their own country, providing information on: 1) Access to NIPT, 2) NIPT's chromosomal coverage, 3) financial coverage of NIPT for the patient and 4) the proportion of women using NIPT in pregnancy. Some data are best clinical estimates, due to a lack of national data.

### Results

In Europe, 14 countries have adopted NIPT into a national policy/program. Two countries (Belgium and the Netherlands) offer NIPT for all pregnant women, whereas most other European countries have implemented NIPT as an offer for higher risk women after first trimester screening. In Australia, both [Combined First Trimester Screening \(cFTS\)](#) or NIPT are used as primary prenatal screening tests. In the USA, there are no national consensus policy on the use of NIPT, however, NIPT is widely implemented. In most European countries offering NIPT, the proportion of women using NIPT is well below 25%. In the Netherlands, Italy, Spain and most Australian and American States, 25-50% of women have NIPT performed and only in Belgium it is above 75%. In most countries NIPT reports on trisomy 13, 18 and 21, and often also on sex chromosome aneuploidies. Only in Belgium, the Netherlands, Lithuania, Greece, Cyprus and Italy is NIPT offered predominantly as a genome-wide test (including some microdeletions or a whole genome coverage).

### Conclusion

NIPT has been widely adopted throughout Europe, Australia and the USA, but only some countries/states have a national policy on the use of NIPT. The variation in NIPT utilization is considerable.

## Keywords

NIPT, Noninvasive prenatal testing, cell-free fetal DNA, cFTS, prenatal genetic screening

## Abbreviations

NIPT	Noninvasive prenatal testing
USA	United States of America
cFTS	Combined First Trimester Screening
SCA	Sex Chromosome Aneuploidies

## Key message

NIPT has been widely adopted, but only some countries/states have a national policy on the use of NIPT. If a strategy has been chosen there seems 2 major set-ups: 1) An offer of NIPT-for-all or more commonly 2) NIPT for women of higher risk identified at Combined First Trimester Screening or by age. When looking in greater detail, similarities cease and almost all national models are unique.

## Introduction

Noninvasive prenatal testing (NIPT) screens maternal plasma for fetal aneuploidies by utilizing cell-free “fetal” DNA (cffDNA) originating from placental apoptosis. Multiple studies have validated the clinical application of NIPT as a sensitive screening tool for the common fetal aneuploidies (1, 2). NIPT has been introduced as an alternative to traditional invasive testing procedures (chorionic villus sampling/amniocentesis) to avoid the small risk of procedure related miscarriage (3, 4). However, NIPT is a screening tool and is limited by not being able to reliably identify the majority of “atypical” chromosomal anomalies (i.e. microdeletions and -duplications), many of which have phenotypical importance (5, 6). Because of the false positive results inherent in any screening test most guidelines recommend that a ‘screen positive’ NIPT result should be confirmed by invasive diagnostics (7).

NIPT was introduced in 2011, initially being launched by commercial providers (8). In recent years, NIPT has been implemented into public healthcare systems as either a first line test, or as a supplement to existing prenatal screening programs (9, 10). The increased use of NIPT has significantly reduced the number of invasive tests performed in many places (11-13).

Because of the rapid development in prenatal diagnostics, there are no temporal data on the current use of NIPT in the western world. The aim of this study is to examine the current use of NIPT in Europe, Australia and the USA.

## Materials and Methods

In order to examine the current use of NIPT in Europe, Australia and the USA, we conducted a simple email-based survey covering four areas of interest: 1) National access to NIPT i.e. NIPT as a national policy, 2) NIPT’s chromosomal coverage (which model of coverage is most frequently used), 3) NIPT’s financial coverage (is NIPT publicly funded, are costs reimbursed via insurance, are costs out-of-pocket), and 4) the proportion of women receiving NIPT (see supplementary material table S1 for original questionnaire). To ensure that our results remained simple and manageable, those completing the survey were required to choose between three or four possible answers. Regarding question 4) the proportion of women receiving NIPT, we provided a “best clinical estimate” option, to be used where national/state data were not available. We utilized our network of recognized national experts to contact colleagues who we felt would be able to complete the survey according to NIPT’s use within their own country and emailed a copy of the questionnaire to confirmed participants in September 2019. [We used the gradually growing study-group to collect information on colleagues in as many countries as possible.](#)



In the USA there is no national policies on the use of NIPT. In the USA access to NIPT depends on individual insurance companies and State Medicaid programs, thus, some questions in the questionnaire ~~was~~ were not appropriate to describe the use of NIPT in the USA. Data from the USA were provided as an expert statement from professor Ron Wapner, who also conceptualized the idea behind the maps.

Data was graphically presented in maps created with Mapchart.net.

## Results

### Europe

We invited ~~2934~~ countries from Europe to participate in the survey and of these, ~~2830~~ returned a fulfilled questionnaire (~~data missing on no reply from -Austria~~ Switzerland, North Macedonia, Serbia and Montenegro). ~~We were not able to obtain contact information on colleagues in the remaining European countries; hence they were not included in the survey (Figure 1-4, grey areas).~~ NIPT has ~~to some extent~~ been adopted in all ~~the~~ European countries ~~that replied to the survey~~ but ~~it~~ is unevenly applied (see figure 1). NIPT is still used by less than 25% of women in most European countries and often in less than 5%. In Italy, the Netherlands, Spain and Belgium NIPT is more widely used (see figure 2).

### Northern Europe

~~In Northern Europe, all countries~~ All Nordic European countries offer Combined First Trimester Screening (cFTS) to either all women or to selected groups. At cFTS a risk estimate is calculated based on maternal age, ultrasound-determined nuchal translucency, and maternal blood tests. If the risk is found to be high (and definitions of “high” vary substantially) then women are offered either invasive testing or NIPT. Some countries offer only invasive testing to women with the very highest risk (e.g. above 1:50 or 1:100), providing NIPT to a slightly lower-risk subset of higher risk women (e.g. between 1:100 and 1:1000). All prenatal screening costs are fully covered by the Nordic national health care systems. In Iceland, high-risk women are offered invasive testing, but if they specifically request NIPT this is complied with, and costs are covered publicly. In the United Kingdom, Wales is the only country to have integrated NIPT in public prenatal screening, offering NIPT as a financially-covered alternative to invasive testing in high risk women after cFTS. NIPT is not currently offered as a commissioned test within the Antenatal Screening pathway in England, Scotland or Ireland. This is anticipated to change next year (2020). In Latvia and Estonia there is no national policy including NIPT, but in Estonia, NIPT providers are negotiating with health insurance companies about provision for high risk patients. Lithuania offer self-financed NIPT to high and intermediate risk women after cFTS.

## Eastern Europe

In [Slovakia](#), Russia and the Czech Republic, there are no publicly-funded offers of NIPT, and NIPT is self-financed through private clinics. Poland and Romania offer only invasive testing after cFTS to the women with the very highest risk (above 1:100), and then NIPT to higher risk women (1:100-1:1000). NIPT is self-financed.

## Southern Europe

In Spain there is no national policy on the use of NIPT. Some regions, like Madrid province, have decided to offer NIPT to high risk patients. In other regions without official programs, different hospitals have incorporated NIPT according to their needs and budget, and in these cases NIPT is publicly financed. Due to extensive use of NIPT in the private sector, the proportion of women receiving NIPT in Spain is high (25-50%, *see figure 3*). In Portugal, a public guideline on NIPT is under preparation, but like Spain, some public clinics already offer NIPT to high risk patients. In Italy, there are official guidelines supporting the use of NIPT to women of high risk, but only two regions currently reimburse the test (Toscana and province of Bolzano). Italy has a high use of NIPT (25-50%) through private clinics. In Greece and Cyprus there are no national guidelines/policies of NIPT, but NIPT is available as a self-financed service. In Slovenia, there is only an offer of NIPT if invasive testing is contraindicated by maternal factors, and in such cases NIPT is publicly financed.

## Western Europe

France offers NIPT to high-risk women after cFTS free of charge. However, women receive results on [Trisomy 21](#) only, and not for [Trisomy 13](#) or [18](#) with NIPT. In Germany, a national decision on the use of NIPT is pending, and NIPT will most likely be offered for high-risk women and with public reimbursement. Since 2017, NIPT has been available to all pregnant women in the Netherlands (as a result of the TRIDENT-2 study, [a nationwide study which allows for all pregnant women to have NIPT performed](#)) as a first line screening test, but less than 42% of women opt for NIPT (14). NIPT is partially self-paid and partially reimbursed. In Belgium NIPT is offered to all pregnant women in addition to ultrasound (excluding biomarkers and thus cFTS) and is reimbursed by insurance. The proportion of women opting for NIPT is very high (>75%). [In Austria there is no national policy on the use of NIPT, however, the estimated use of NIPT is considerable \(25-50%\).](#)

## NIPT chromosomal coverage in Europe

In five European countries, NIPT primarily covers chromosome 13, 18 and 21 only. In nine countries, NIPT also covers sex chromosome aneuploidies, and four countries offer a choice between these two options. The Netherlands, Belgium, Lithuania, Italy, Cyprus and Greece primarily offer NIPT for 13, 18, 21, sex

chromosome aneuploidy, microdeletions and/or whole-genome coverage (i.e. NIPT including some microdeletions, with or without SCA or whole genome coverage) (*see figure 4*).

## Australia

We received data from six out of eight states (no data were received from Northern Territory or Western Australia). The Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) find both cFTS and NIPT as acceptable primary prenatal screening tests.

In Victoria state, cFTS is partially government financed, whereas NIPT is self-funded. It is estimated that 25-50% of the pregnant population in Victoria choose NIPT as first line screening test, similarly to the Australian Capital Territory, Tasmania and South Australia. In New South Wales and Queensland less than 25% of the pregnant population have NIPT performed (*see figure 6*). NIPT coverage in Australia generally varies by provider more than by state.

## The USA

In the USA, nearly all commercial insurance companies cover NIPT for high risk patients (i.e. >35 years, positive cFTS etc.) as do most ~~S~~state sponsored Medicaid programs. In six states, Medicaid programs also cover NIPT for average risk women. In nine states, Medicaid programs do not cover NIPT at all (*see figure 5*). It is estimated that 25-50% of all pregnant women receive NIPT. NIPT covering chromosome 13, 18, 21 and sex chromosome aneuploidies is most frequently used although screening for rare aneuploidies, triploidy, and some microdeletions is available but not recommended.

## Discussion

Here, we present data on the current use of NIPT within Europe, Australia and the USA. All countries [that replied to the survey](#) have NIPT in use (private or public), and many countries/states have guidelines or policies (present or currently being planned/drafted), and/or laws regulating its use. There appear to be two main strategies for NIPT's implementation: 1) NIPT is offered after high risk cFTS, or 2) NIPT is offered as first line test for all. The current uptake of NIPT varies greatly. Although less than 25% of women in most European countries currently use NIPT, uptake is higher within the Netherlands, Italy, ~~and~~ Spain [and Austria](#), where 25-50% of women use NIPT, and in Belgium uptake is higher again (being above 75%). In most American and Australian states, 25-50% of the pregnant population have NIPT performed.

We found much variation in the way in which NIPT is used worldwide, as well as between the different European countries. In some countries, recommendations regarding NIPT even vary from region to region.

The simplicity of this survey, and thus the final graphics produced, means we are unlikely to have demonstrated the full range and depth of this diversity.

Figure 1 presents a seemingly homogeneous picture of NIPT in [Northern Europe/the Nordic European countries](#), where all countries have implemented NIPT after cFTS. However, the ways in which NIPT is practiced are very different. Norway offer cFTS only to women above 38 years of age or after a previously complicated pregnancy etc. (10). Therefore, only around 10 % of all pregnant women are offered cFTS. Of these, 10% (1% of pregnant women) are at high risk following cFTS and are offered NIPT. Other differences, not adequately covered by our data/figures, relate to the effect of NIPT on invasive-testing rates. In Denmark the introduction of NIPT has not affected invasive rates, and invasive rates are even increasing (15), whereas in Finland invasive rates were halved by the introduction of NIPT ~~(private data, VS)~~ [\(data from professor Vedran Stefanovic, no reference\)](#)- [In Denmark, women are offered Chromosomal Microarray \(CMA\) after invasive testing. In Finland, women are offered trisomy PCR, thus, the diagnostic gain of invasive testing compared with NIPT is greater in Denmark.](#)

France appears to be relatively comparable to the Nordic [European](#) countries with the offer of NIPT after cFTS. An interesting resemblance is found between France and Norway, as both countries have laws to restrict the use of NIPT only to some groups (Norway) or to some disorders (France). In Norway it is illegal to offer cFTS or NIPT to women under the age of 38 (10). In France, all blood-based prenatal screening is subjected to laboratory authorization by national authority. For NIPT specifically, a law was only recently passed to make testing for ~~t~~trisomy 21 available for authorization, and authorization for ~~t~~trisomy 13 and 18 is not yet available. Thus, there seems to have been an additional need, above that which was contained within existing national policies on prenatal screening, to regulate the use of NIPT.

The Netherlands and Belgium offer NIPT as a first line test for all women, but their specific models of use still differ significantly. In the Netherlands the proportion of women using NIPT is low (<42%), but the uptake for cFTS was also low prior to the introduction of NIPT (14). -NIPT is currently offered without cFTS, and it is uncertain whether this offer will remain the same once the national TRIDENT study is complete (14). In Belgium NIPT is offered to all pregnant women, alongside first trimester ultrasound with nuchal translucency measurement, but without biomarkers. Here, uptake is much higher than in the Netherlands. One potential explanation for this difference could be that in Belgium NIPT is fully reimbursed, whereas reimbursement is only partial in the Netherlands. Both countries have implemented genome-wide NIPT (whole genome coverage with a resolution of potentially 10-20 Mb). [The exact role of genome-wide NIPT, however, is a topic of considerable professional disagreement](#) (16) [and has likely not yet found its final form or place in prenatal screening.](#)

It is difficult to compare the use of NIPT in Europe to use in Australia and the USA, because of the major differences in the structure of the respective health care systems. In the USA, NIPT's use depends primarily on insurance company and state Medicaid policy. Within their most recent recommendations (2016), the American College of Obstetricians and Gynecologists suggests that NIPT is a valid alternative to invasive testing in patients identified as high risk after first trimester screening (7). Medicaid programs, which provide health coverage to millions of Americans, cover NIPT for high risk patients. However, NIPT is not covered in nine states, and in Washington DC (*see figure 5*). NIPT is covered [by insurers](#) for at least 114 million women ~~who reimburse testing for~~ [with](#) average risk singleton pregnancies. ~~h~~ However, more than 70 million women are insured by providers who do not currently cover/reimburse NIPT for average risk women. -In Australia, NIPT can be used as an alternative to cFTS for primary screening. An application for government NIPT subsidy is currently under revision with two models proposed: 1) universal screening with NIPT or 2) NIPT after high risk cFTS. These two models are also the most commonly used strategies around Europe.

Our findings are limited by the simplicity of the questionnaire and the resulting data provided by our colleagues. [We were not able to obtain information from all European countries, and “missing” data were prevailing in the south-eastern part of Europe. Thus, the use of NIPT in this part of Europe remains uncertain.](#) Some data are provided as a “best clinical estimates”, where national data were not available (see supplementary table and figures). Much of the details and complexity relating to NIPT's use within and across countries ~~are~~ thus not addressed here. NIPT continues to develop rapidly in terms of resolution, price and implementation, and our comparison may thus have a short time-window of relevance. We did not investigate whether NIPT had increased or decreased the total number of fetal chromosomal aberrations detected in each country, nor did we focus on the price of NIPT in each country, which may greatly influence the number of women receiving NIPT. In a study from 2015, Minear *et al.* found the price of NIPT varied from \$350 USD (Australia) to \$2900 USD (USA)(8). The overall price has likely decreased in recent years, and this may have effected uptake. The price of testing also differs greatly within Europe—~~for instance,~~ ~~within central Europe,~~ NIPT may be offered for free (e.g. being covered by the NHS), or prices may start from 150 to 300 Euro. ~~within Southern Europe the price of the same test from the same companies, may be >1000 Euro (17).~~ Specific national economic, social, and cultural contexts are likely to affect the extent to which NIPT is offered and accepted. Further, in most countries, NIPT is also available as a self-paid service through the private sector, the uptake and outcomes of which may be more difficult to monitor ([reference paper by Ida Lund submitted to same AOGS edition](#)).

## Conclusion

NIPT is implemented in all countries studied. Some countries have national policies and many more policies are in the pipeline. Where a specific strategy has been chosen, there appears to be two popular models of provision: 1) An offer of NIPT-for-all or 2) NIPT for women of risk identified at cFTS. Some countries have enacted specific legislation on the use of prenatal screening and/or NIPT. In most European countries less than 25% of women have NIPT performed. In the US and Australia NIPT is more widely used. When looking in greater detail, similarities cease and almost all models are unique.

## References

1. Gil MM, Accurti V, Santacruz B, Plana MN, Nicolaides KH. Analysis of cell-free DNA in maternal blood in screening for aneuploidies: updated meta-analysis. *Ultrasound Obstet Gynecol.* 2017;50(3):302-14.
2. Iwarsson E, Jacobsson B, Dagerhamn J, Davidson T, Bernabe E, Heibert Arnlind M. Analysis of cell-free fetal DNA in maternal blood for detection of trisomy 21, 18 and 13 in a general pregnant population and in a high risk population - a systematic review and meta-analysis. *Acta Obstet Gynecol Scand.* 2017;96(1):7-18.
3. Tabor A, Alfirevic Z. Update on procedure-related risks for prenatal diagnosis techniques. *Fetal Diagn Ther.* 2010;27(1):1-7.
4. Wulff CB, Gerds TA, Rode L, Ekelund CK, Petersen OB, Tabor A. Risk of fetal loss associated with invasive testing following combined first-trimester screening for Down syndrome: a national cohort of 147,987 singleton pregnancies. *Ultrasound Obstet Gynecol.* 2016;47(1):38-44.
5. Petersen OB, Vogel I, Ekelund C, Hyett J, Tabor A, Danish Fetal Medicine Study G, et al. Potential diagnostic consequences of applying non-invasive prenatal testing: population-based study from a country with existing first-trimester screening. *Ultrasound Obstet Gynecol.* 2014;43(3):265-71.
6. Wapner RJ, Martin CL, Levy B, Ballif BC, Eng CM, Zachary JM, et al. Chromosomal microarray versus karyotyping for prenatal diagnosis. *N Engl J Med.* 2012;367(23):2175-84.
7. Committee on Practice Bulletins-Obstetrics CoG, the Society for Maternal-Fetal M. Practice Bulletin No. 163: Screening for Fetal Aneuploidy. *Obstet Gynecol.* 2016;127(5):e123-37.
8. Minear MA, Lewis C, Pradhan S, Chandrasekharan S. Global perspectives on clinical adoption of NIPT. *Prenat Diagn.* 2015;35(10):959-67.
9. van Schendel RV, van El CG, Pajkrt E, Henneman L, Cornel MC. Implementing non-invasive prenatal testing for aneuploidy in a national healthcare system: global challenges and national solutions. *BMC Health Serv Res.* 2017;17(1):670.
10. Helsenorge. Fosterdiagnostikk: 2019 [Available from: <https://helsenorge.no/undersokelse-og-behandling/fosterdiagnostikk>].
11. Larion S, Warsof SL, Romary L, Mlynarczyk M, Peleg D, Abuhamad AZ. Uptake of noninvasive prenatal testing at a large academic referral center. *Am J Obstet Gynecol.* 2014;211(6):651 e1-7.
12. Chan YM, Leung WC, Chan WP, Leung TY, Cheng YK, Sahota DS. Women's uptake of non-invasive DNA testing following a high-risk screening test for trisomy 21 within a publicly funded healthcare system: findings from a retrospective review. *Prenat Diagn.* 2015;35(4):342-7.
13. Chetty S, Garabedian MJ, Norton ME. Uptake of noninvasive prenatal testing (NIPT) in women following positive aneuploidy screening. *Prenat Diagn.* 2013;33(6):542-6.
14. van der Meij KRM, Sistermans EA, Macville MVE, Stevens SJC, Bax CJ, Bekker MN, et al. TRIDENT-2: national implementation of genome-wide non-invasive prenatal testing as a first-tier screening test in the Netherlands. *The American Journal of Human Genetics.* 2019;105(6):1091-101.
15. The Danish Cytogenetic Centralregister (DCCR). Danish Invasive rates 2018 [Available from: [https://www.auh.dk/siteassets/afdelinger/klinisk-genetisk-afdeling/dccr/pdf/pn-am-cvs\\_1970-2018.pdf](https://www.auh.dk/siteassets/afdelinger/klinisk-genetisk-afdeling/dccr/pdf/pn-am-cvs_1970-2018.pdf)].
16. Jani JC, Gil MM, Benachi A, Prefumo F, Kagan KO, Tabor A, et al. Genome-wide cfDNA testing of maternal blood. *Ultrasound in Obstetrics & Gynecology.* 2020;55(1):13-4.
17. Thomas Liehr. Non-invasive prenatal testing – safer or simply more profitable? May 20, 2019 [Available from: <https://atlasofscience.org/non-invasive-prenatal-testing-safer-or-simply-more-profitable/>].

## Figures

### *Figure 1*

NIPT as a national prenatal offer [in Europe](#)

### *Figure 2*

NIPT financial coverage [in Europe](#).

Stripes indicates two possible options within the same country. See text for details.

### *Figure 3*

Proportion of women receiving NIPT in Europe.

Best clinical guess: [A](#), CZ, ES, HR, IT, PL, RO, RU, SE, [SK](#), WAL

### *Figure 4*

NIPT chromosomal coverage [in Europe](#)

Stripes indicate that two options exist and are used fairly evenly. In France, NIPT only reports on chromosome 21.

### *Figure 5*

NIPT coverage by State Medicaid programs

### *Figure 6*

Proportion of women receiving NIPT in Australia. Best clinical guesses.

### *Supplementary Table S1*

Original questionnaire